CLRB
Price
$0.28
Change
-$0.00 (-0.00%)
Updated
Mar 4, 10:57 AM (EDT)
Capitalization
12.81M
Earnings call today
ENTA
Price
$7.10
Change
-$0.23 (-3.14%)
Updated
Mar 4, 11:04 AM (EDT)
Capitalization
165.97M
69 days until earnings call
Ad is loading...

CLRB vs ENTA

Header iconCLRB vs ENTA Comparison
Open Charts CLRB vs ENTABanner chart's image
Cellectar Biosciences
Price$0.28
Change-$0.00 (-0.00%)
Volume$431
Capitalization12.81M
Enanta Pharmaceuticals
Price$7.10
Change-$0.23 (-3.14%)
Volume$200
Capitalization165.97M
CLRB vs ENTA Comparison Chart
Loading...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLRB vs. ENTA commentary
Mar 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRB is a Buy and ENTA is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 04, 2025
Stock price -- (CLRB: $0.28 vs. ENTA: $7.31)
Brand notoriety: CLRB and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRB: 38% vs. ENTA: 32%
Market capitalization -- CLRB: $12.81M vs. ENTA: $165.97M
CLRB [@Biotechnology] is valued at $12.81M. ENTA’s [@Biotechnology] market capitalization is $165.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $398.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.48B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRB’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • CLRB’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRB’s TA Score shows that 5 TA indicator(s) are bullish while ENTA’s TA Score has 5 bullish TA indicator(s).

  • CLRB’s TA Score: 5 bullish, 4 bearish.
  • ENTA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CLRB and ENTA are a good buy in the short-term.

Price Growth

CLRB (@Biotechnology) experienced а -5.09% price change this week, while ENTA (@Biotechnology) price change was -12.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.35%. For the same industry, the average monthly price growth was -11.04%, and the average quarterly price growth was -7.19%.

Reported Earning Dates

CLRB is expected to report earnings on May 12, 2025.

ENTA is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTA($166M) has a higher market cap than CLRB($12.8M). ENTA YTD gains are higher at: 27.130 vs. CLRB (-6.990). CLRB has higher annual earnings (EBITDA): -51.29M vs. ENTA (-104.51M). ENTA has more cash in the bank: 248M vs. CLRB (34.3M). CLRB has less debt than ENTA: CLRB (513K) vs ENTA (55.5M). ENTA has higher revenues than CLRB: ENTA (67.6M) vs CLRB (0).
CLRBENTACLRB / ENTA
Capitalization12.8M166M8%
EBITDA-51.29M-104.51M49%
Gain YTD-6.99027.130-26%
P/E RatioN/AN/A-
Revenue067.6M-
Total Cash34.3M248M14%
Total Debt513K55.5M1%
FUNDAMENTALS RATINGS
CLRB vs ENTA: Fundamental Ratings
CLRB
ENTA
OUTLOOK RATING
1..100
1819
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
6644
P/E GROWTH RATING
1..100
751
SEASONALITY SCORE
1..100
n/a35

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (74) in the Biotechnology industry is in the same range as ENTA (96). This means that CLRB’s stock grew similarly to ENTA’s over the last 12 months.

CLRB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENTA (100). This means that CLRB’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (95) in the Biotechnology industry is in the same range as CLRB (100). This means that ENTA’s stock grew similarly to CLRB’s over the last 12 months.

ENTA's Price Growth Rating (44) in the Biotechnology industry is in the same range as CLRB (66). This means that ENTA’s stock grew similarly to CLRB’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CLRB (75). This means that ENTA’s stock grew significantly faster than CLRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLRBENTA
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 8 days ago
70%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAZEX19.310.16
+0.84%
Oakmark International Small Cap R6
GUBGX15.84N/A
N/A
Victory RS International A
GSZPX26.65N/A
N/A
Goldman Sachs Small Cap Gr Insghts P
FLIAX10.44N/A
N/A
First Sentier American Listed Infras Ins
DFVEX27.03-0.53
-1.92%
DFA US Vector Equity I

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with ADCT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-3.94%
ADCT - CLRB
46%
Loosely correlated
-9.66%
ANAB - CLRB
44%
Loosely correlated
-12.96%
QTTB - CLRB
39%
Loosely correlated
-4.85%
CELC - CLRB
37%
Loosely correlated
-5.73%
IBRX - CLRB
37%
Loosely correlated
-13.53%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-6.04%
CLRB - ENTA
40%
Loosely correlated
-3.94%
AKRO - ENTA
35%
Loosely correlated
-7.29%
ALEC - ENTA
34%
Loosely correlated
-13.41%
AXON - ENTA
34%
Loosely correlated
-0.44%
AURA - ENTA
34%
Loosely correlated
-3.74%
More